Xeroderma pigmentosum (XP) is a rare autosomal recessive genodermatosis associated with hypersensitivity to ultraviolet radiation (UVR), being due to defects involving the nucleotide excision repair pathway. Patients with XP are prone to develop multiple cutaneous neoplasms including non-melanoma skin cancers and melanoma. Collision tumors in patients with XP have been reported in the literature including the following lesions, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and in situ melanoma. Herein, we present a rare collision tumor composed of melanoma and basosquamous carcinoma in a 13-year-old XP patient and describe the dermoscopic features.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.14097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basosquamous Carcinoma Arising from the Vulva: A Case Report.
Case Rep Oncol
November 2024
Faculty of Medicine of Tunis, University of Tunis Manar, Tunis, Tunisia.
Article Synopsis
- * A case study of a 59-year-old woman showed a painful, slow-growing vulvar lesion diagnosed as BSC, confirmed by biopsy and treated with partial radical vulvectomy and sentinel lymph node biopsy, both showing no evidence of metastasis.
- * This case highlights the importance of recognizing squamous differentiation in BSC for ensuring complete surgical excision, as it has a higher risk of recurrence and metastasis compared to basal cell carcinoma,
Frequent Occurrence of High-Risk Basal Cell Carcinoma in Xeroderma Pigmentosum: A Histopathological Insight From an Indian Cohort.
J Cutan Pathol
November 2024
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
Background: Xeroderma pigmentosum (XP) is a genodermatosis, characterized both by premature aging and significantly increased risk of non-melanoma and melanoma skin cancers at an early age. However, limited literature is available on the common histopathological subtypes of basal cell carcinoma (BCC) in these patients.
Methods: In this ambispective case series, we recruited patients of XP who had either a currently present skin tumor or previously excised one, provided their histopathological sections were available.
Basal Cell Carcinoma Cleft: The Missing Piece of the Puzzle.
Cureus
October 2024
Multidisciplinary Integrated Center of Dermatological Interface Research (MIC-DIR), "Dunărea de Jos" University, Galati, ROU.
Background: This study aims to explore the tumor-stroma separation or the cleft characterizing basal cell carcinoma (BCC).
Methodology: In this retrospective cohort investigation, we enrolled 244 patients who received a confirmed diagnosis of BCC through histopathological examination in the period of 2019-2020 at the Pathology Laboratory of the "Sfântul Apostol Andrei" Emergency Clinical Hospital located in Galați, Romania. The identification of patients was accomplished by utilizing electronic health records, and relevant clinical, demographic, and histopathological data were retrieved from the physical database of the Pathology Laboratory.
Use of HSP105 in the Differential Diagnosis of Basaloid Skin Tumors: A Study of 73 Cases.
Appl Immunohistochem Mol Morphol
October 2024
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing.
Background: Basaloid skin tumors include subtypes of basal cell carcinoma (BCC) and the basaloid variant of squamous cell carcinoma (SCC). Due to their similarity in pathology and clinical presentation, their diagnosis is not straightforward. The aim of this study was to analyze the immunohistochemical expression of HSP105 in basaloid skin tumors, which include BCC, basosquamous carcinoma (BSC), metatypical basal cell carcinoma (MBCC), basaloid squamous cell carcinoma (BSCC), BCC with squamous differentiation as well as conventional SCC.
View Article and Find Full Text PDFSecondary cutaneous malignancy after treatment of basal cell carcinoma with hedgehog pathway inhibitor: a systematic review.
Arch Dermatol Res
October 2024
Department of Dermatology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Several studies have been published describing development of cutaneous malignancy after vismodegib therapy; no systematic review has been conducted to interpret these data. Our objective was to systemically review reported cases of same-site or different-site cutaneous malignancy after smoothened inhibitor (SMOi) therapy for primary basal cell carcinoma (BCC). PubMed, CINAHL, and Scopus were systematically searched January 1, 2012 - March 28, 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!